Exploring Cognitive and Neuroimaging Profiles of Dementia Subtypes of Individuals with Dementia in the Democratic Republic of Congo

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2025 Feb 27

PMID 40013096

Authors

Jean Ikanga

Saranya Sundaram Patel

Megan Schwinne

Caterina Obenauf

Emmanuel Epenge

Guy Gikelekele

Nathan Tshengele

Immaculee Kavugho

Samuel Mampunza

Lelo Mananga

Charlotte E Teunissen

Julio C Rojas

Brandon Chan

Argentina Lario Lago

Joel H Kramer

Adam L Boxer

Andreas Jeromin

Emile Omba

Alvaro Alonso

Alden L Gross

Affiliations

Soon will be listed here.

Abstract

Objective: The 2024 Alzheimer's Association (AA) research diagnostic criteria for Alzheimer's Disease (AD) considers fluid biomarkers, including promising blood-based biomarkers for detecting AD. This study aims to identify dementia subtypes and their cognitive and neuroimaging profiles in older adults with dementia in the Democratic Republic of Congo (DRC) using biomarkers and clinical data.

Methods: Forty-five individuals with dementia over 65 years old were evaluated using the Community Screening Instrument for Dementia and the informant-based Alzheimer's Questionnaire. Core AD biomarkers (Aβ42/40 and p-tau181) and non-specific neurodegeneration biomarkers (NfL, GFAP) were measured in blood plasma. Neuroimaging structures were assessed using magnetic resonance imaging (MRI). Dementia subtypes were determined based on plasma biomarker pathology and vascular markers. Biomarker cutoff scores were identified to optimize sensitivity and specificity. Individuals were stratified into one of four dementia subtypes-AD only, non-AD vascular, non-AD other, or mixed - based on combinations of abnormalities in these markers.

Results: Among the 45 individuals with dementia, mixed dementia had the highest prevalence (42.4%), followed by AD-only (24.4%), non-AD other dementia (22.2%), and non-AD vascular dementia subtypes (11.1%). Both cognitive and neuroimaging profiles aligned poorly with biomarker classifications in the full sample. Cognitive tests varied across dementia subtypes. The cognitive profile of the AD-only and mixed groups suggested relatively low cognitive performance, while the non-AD and other groups had the best scores on average.

Conclusion: Consistent with studies in other settings, our preliminary findings suggest that neurodegenerative plasma biomarkers may help to identify dementia subtypes and provide insight into cognitive and neuroimaging profiles among older adults in the DRC.

References

Maclin J, Wang T, Xiao S . Biomarkers for the diagnosis of Alzheimer's disease, dementia Lewy body, frontotemporal dementia and vascular dementia. Gen Psychiatr. 2019; 32(1):e100054. PMC: 6551430. DOI: 10.1136/gpsych-2019-100054. View

Liss J, Seleri Assuncao S, Cummings J, Atri A, Geldmacher D, Candela S . Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021; 290(2):310-334. PMC: 8359937. DOI: 10.1111/joim.13244. View

. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7(2):e105-e125. PMC: 8810394. DOI: 10.1016/S2468-2667(21)00249-8. View

Enkirch S, Traschutz A, Muller A, Widmann C, Gielen G, Heneka M . The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology. 2018; 288(1):226-333. DOI: 10.1148/radiol.2018171888. View

Jack Jr C, Scott Andrews J, Beach T, Buracchio T, Dunn B, Graf A . Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024; 20(8):5143-5169. PMC: 11350039. DOI: 10.1002/alz.13859. View

Imarhiagbe F, Ogunrin O, Ogunniyi A . Cognitive performance of hypertensive elderly Nigerians: a case control study. Afr J Med Med Sci. 2006; 34(3):269-73. View

Ashton N, Hye A, Rajkumar A, Leuzy A, Snowden S, Suarez-Calvet M . An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. 2020; 16(5):265-284. DOI: 10.1038/s41582-020-0348-0. View

Dodge H, Zhu J, Woltjer R, Nelson P, Bennett D, Cairns N . Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. Alzheimers Dement. 2016; 13(6):613-623. PMC: 5466467. DOI: 10.1016/j.jalz.2016.11.003. View

Jack Jr C, Therneau T, Weigand S, Wiste H, Knopman D, Vemuri P . Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. JAMA Neurol. 2019; 76(10):1174-1183. PMC: 6632154. DOI: 10.1001/jamaneurol.2019.1971. View

10.

Claus J, Staekenborg S, Holl D, Roorda J, Schuur J, Koster P . Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. Eur Radiol. 2017; 27(8):3147-3155. PMC: 5491609. DOI: 10.1007/s00330-016-4726-3. View

11.

Mattsson N, Cullen N, Andreasson U, Zetterberg H, Blennow K . Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7):791-799. PMC: 6583067. DOI: 10.1001/jamaneurol.2019.0765. View

12.

Kowall B, Rathmann W . HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?. Diabetes Metab Syndr Obes. 2013; 6:477-91. PMC: 3848642. DOI: 10.2147/DMSO.S39093. View

13.

Hu Y, Kirmess K, Meyer M, Rabinovici G, Gatsonis C, Siegel B . Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Netw Open. 2022; 5(4):e228392. PMC: 9024390. DOI: 10.1001/jamanetworkopen.2022.8392. View

14.

Slot R, Sikkes S, Berkhof J, Brodaty H, Buckley R, Cavedo E . Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimers Dement. 2018; 15(3):465-476. PMC: 6465066. DOI: 10.1016/j.jalz.2018.10.003. View

15.

Oeckl P, Anderl-Straub S, von Arnim C, Baldeiras I, Diehl-Schmid J, Grimmer T . Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry. 2022; . DOI: 10.1136/jnnp-2021-328547. View

16.

Wahlund L, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M . A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001; 32(6):1318-22. DOI: 10.1161/01.str.32.6.1318. View

17.

Farombi T, Owolabi M, Ogunniyi A . Falls and Their Associated Risks in Parkinson's Disease Patients in Nigeria. J Mov Disord. 2016; 9(3):160-5. PMC: 5035939. DOI: 10.14802/jmd.16011. View

18.

Malek-Ahmadi M, Sabbagh M . Development and Validation of the Alzheimer's Questionnaire (AQ). J Nat Sci. 2015; 1(5):e104. PMC: 4423544. View

19.

Assfaw A, Schindler S, Morris J . Advances in blood biomarkers for Alzheimer disease (AD): A review. Kaohsiung J Med Sci. 2024; 40(8):692-698. DOI: 10.1002/kjm2.12870. View

20.

Van Harten A, Wiste H, Weigand S, Mielke M, Kremers W, Eichenlaub U . Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays. Alzheimers Dement. 2021; 18(4):635-644. PMC: 9249966. DOI: 10.1002/alz.12406. View